ESPR
Price
$1.99
Change
-$0.14 (-6.57%)
Updated
Apr 25, 6:59 PM EST
12 days until earnings call
VTRS
Price
$11.48
Change
+$0.01 (+0.09%)
Updated
Apr 25, 2:59 PM EST
13 days until earnings call
Ad is loading...

Compare predictions ESPR vs VTRS

Header iconESPR vs VTRS Comparison
Open Charts ESPR vs VTRSBanner chart's image
Esperion Therapeutics
Price$1.99
Change-$0.14 (-6.57%)
Volume$2.97M
CapitalizationN/A
Viatris
Price$11.48
Change+$0.01 (+0.09%)
Volume$113.56K
CapitalizationN/A
View a ticker or compare two or three
ESPR vs VTRS Comparison Chart

Loading...

ESPRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VTRSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ESPR vs. VTRS commentary
Apr 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a StrongSell and VTRS is a Hold.

COMPARISON
Comparison
Apr 26, 2024
Stock price -- (ESPR: $1.99 vs. VTRS: $11.47)
Brand notoriety: ESPR and VTRS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ESPR: 76% vs. VTRS: 74%
Market capitalization -- ESPR: $495.94M vs. VTRS: $14.18B
ESPR [@Pharmaceuticals: Other] is valued at $495.94M. VTRS’s [@Pharmaceuticals: Other] market capitalization is $14.18B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • ESPR’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, VTRS is a better buy in the long-term than ESPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 5 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • ESPR’s TA Score: 5 bullish, 5 bearish.
  • VTRS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than ESPR.

Price Growth

ESPR (@Pharmaceuticals: Other) experienced а +6.42% price change this week, while VTRS (@Pharmaceuticals: Other) price change was +3.15% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.91%. For the same industry, the average monthly price growth was +25.05%, and the average quarterly price growth was +18905.26%.

Reported Earning Dates

ESPR is expected to report earnings on Jul 30, 2024.

VTRS is expected to report earnings on Aug 05, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (-0.91% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for ESPR with price predictions.
OPEN
A.I.dvisor published
a Summary for VTRS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
VTRS($14.2B) has a higher market cap than ESPR($496M). VTRS YTD gains are higher at: 6.950 vs. ESPR (-33.445). VTRS has higher annual earnings (EBITDA): 3.52B vs. ESPR (-150.11M). VTRS has more cash in the bank: 1.18B vs. ESPR (82.2M). ESPR has less debt than VTRS: ESPR (266M) vs VTRS (18.4B). VTRS has higher revenues than ESPR: VTRS (15.4B) vs ESPR (116M).
ESPRVTRSESPR / VTRS
Capitalization496M14.2B3%
EBITDA-150.11M3.52B-4%
Gain YTD-33.4456.950-481%
P/E RatioN/A238.80-
Revenue116M15.4B1%
Total Cash82.2M1.18B7%
Total Debt266M18.4B1%
FUNDAMENTALS RATINGS
ESPR vs VTRS: Fundamental Ratings
ESPR
VTRS
OUTLOOK RATING
1..100
7373
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
17
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10089
PRICE GROWTH RATING
1..100
4046
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
1550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (17) in the null industry is in the same range as ESPR (29) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ESPR’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as ESPR (100) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ESPR’s over the last 12 months.

VTRS's SMR Rating (89) in the null industry is in the same range as ESPR (100) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (40) in the Biotechnology industry is in the same range as VTRS (46) in the null industry. This means that ESPR’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for ESPR (100) in the Biotechnology industry. This means that VTRS’s stock grew significantly faster than ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRVTRS
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
71%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
65%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
60%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
Bearish Trend 10 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
61%
View a ticker or compare two or three
Ad is loading...
ESPRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VTRSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PDEQX15.270.08
+0.53%
PGIM Jennison Emerging Markets Eq OppsR6
JEMZX8.71-0.02
-0.23%
JHancock Emerging Markets Equity C
SSBIX11.53-0.04
-0.35%
State Street Balanced Index K
CEYRX92.74-0.43
-0.46%
Calvert Equity R6
SCIUX10.41-0.06
-0.57%
Invesco Income Advantage U.S. Fund R5

ESPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ESPR has been loosely correlated with ELAN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ESPR jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
-6.57%
ELAN - ESPR
36%
Loosely correlated
-2.03%
PAHC - ESPR
31%
Poorly correlated
-0.96%
DCPH - ESPR
31%
Poorly correlated
-3.01%
RMTI - ESPR
29%
Poorly correlated
+1.34%
PTPI - ESPR
29%
Poorly correlated
+0.87%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with PRGO. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-0.69%
PRGO - VTRS
40%
Loosely correlated
+0.13%
TEVA - VTRS
38%
Loosely correlated
+1.84%
ELAN - VTRS
37%
Loosely correlated
-2.03%
ALKS - VTRS
34%
Loosely correlated
-0.85%
PAHC - VTRS
32%
Poorly correlated
-0.96%
More